Trilipix Advisory Committee Call For Outcomes Trial Could Be Damaged By Niaspan Failure
Executive Summary
Abbott Laboratories is facing a difficult proposition with its cholesterol franchise. At the May 19 review of the ACCORD-Lipid data on use of Trilipix with a statin, FDA's Endocrinologic and Metabolic Drugs Advisory Committee called for outcomes trials to determine whether the combination has value in a particular subpopulation.
You may also be interested in...
Trilipix CV Outcomes Study To Focus On Patients With High Triglycerides, Low HDL-Cholesterol
FDA follows its advisory committee’s recommendation and requires a post-marketing study of Abbott’s fibrate to determine whether combination use with a statin provides a cardiovascular benefit over statin monotherapy in high-risk patients.
More Disheartening News For Abbott Cholesterol Franchise: Niaspan/Statin Study Halted Due To Lack Of Added Benefit
NIH's early termination of the AIM-HIGH trial does further damage to combination therapy for increasing HDL cholesterol and lowering triglycerides in patients with well-controlled LDL cholesterol.
Could ACCORD Results Mean Another Trial For Trilipix?
Advisory committee says data inconclusive with subgroups and recommended another study to determine if there is increased risk in women and/or benefit for high TG, low HDL-C patients.